Anti-CPA3 antibody

Supplementary info

This supplementary information is collated from multiple sources and compiled automatically.

Activity summary

Carboxypeptidase A3 (CPA3) also known as mast cell carboxypeptidase A is an enzyme with a molecular mass of approximately 50 kDa. It belongs to the metallo-carboxypeptidase family and acts as a proenzyme. CPA3 is primarily expressed in mast cells which predominantly reside in connective tissues such as skin respiratory tract and gastrointestinal tract. This protein contributes to the degradation of certain peptides by cleaving carboxy-terminal amino acids particularly aromatic and branched-chain amino acids.

Biological function summary

CPA3 plays an important role in the defense mechanisms of the body. It is involved in the process of mast cell degranulation releasing various mediators that participate in immune responses. CPA3 functions in combination with other enzymes including tryptase and chymase creating a complex interplay for regulating inflammation. It influences vascular permeability and recruitment of other immune cells to sites of infection or injury. Additionally CPA3 can modulate activities of other proteins by processing their precursors or inactivating them.

Pathways

CPA3 integrates into immune response pathways. It contributes significantly to the inflammatory response cascade where it acts alongside proteins like tryptase and chymase to manage the activity of inflammatory peptides. Moreover CPA3 participates in the renin-angiotensin system which affects blood pressure regulation and fluid balance interacting indirectly with angiotensin-converting enzyme (ACE) and others in this critical pathway.

Associated diseases and disorders

CPA3 relates prominently to allergic conditions such as asthma and anaphylaxis. The enzyme's participation in the degradation of peptide substrates influences the intensity and duration of allergic responses. CPA3 activity also correlates with remodeling of airway tissues in chronic respiratory conditions. Its connection with mast cell tryptase highlights its role in the pathology of systemic mastocytosis as increased expression of CPA3 occurs in this disorder affecting clinical manifestations in patients.